Quarterly results · SUNPHARMA
SUN PHARMACEUTICAL IND L reported revenue of ₹16,199 cr and net profit of ₹1,995 cr in Q2 FY27 (quarter ended 30 Sept 2026). Below is the full quarter-wise results table with revenue, operating profit, margins, tax, EPS and annual history — updated when Yahoo Finance publishes updated financial statements; exchange filings can appear earlier.
| Quarter | Q2 FY27 |
|---|---|
| Quarter ended | 30 Sept 2026 |
| Revenue | ₹16,199 cr |
| Revenue YoY | — |
| Operating profit | ₹3,986 cr |
| Operating margin | 24.6% |
| Net profit | ₹1,995 cr |
| Net profit YoY | — |
| Net profit QoQ | -31.1% |
| Net margin | 12.3% |
| Basic EPS | ₹8.30 |
| TTM revenue | ₹61,411 cr |
| TTM net profit | ₹10,973 cr |
| TTM net margin | 17.9% |
SUN PHARMACEUTICAL IND L (SUNPHARMA) has reported its Q2 FY27 results for the quarter ended 2026-09-30. The company posted revenue of ₹16,199 cr and a net profit of ₹1,995 cr, translating into earnings per share of ₹8.30.
Operating profit for the quarter stood at ₹3,986 cr, an operating margin of 24.6%.
Revenue
₹16,199 cr
— YoY
Net profit
₹1,995 cr
— YoY
Operating profit
₹3,986 cr
— YoY
EPS
₹8.30
— YoY
Swipe sideways to see all columns →
| Quarter | Revenue | Operating profit | Net profit | OPM | Net margin | EPS | Profit YoY | Profit QoQ |
|---|---|---|---|---|---|---|---|---|
| Q2 FY272026-09-30 | ₹16,199 cr | ₹3,986 cr | ₹1,995 cr | 24.6% | 12.3% | ₹8.30 | — | -31.1% |
| Q1 FY272026-06-30 | ₹15,184 cr | ₹3,557 cr | ₹2,895 cr | 23.4% | 19.1% | ₹12.10 | +27.0% | +6.7% |
| Q4 FY262026-03-31 | ₹14,560 cr | ₹2,752 cr | ₹2,714 cr | 18.9% | 18.6% | ₹11.30 | +26.2% | -19.4% |
| Q3 FY262025-12-31 | ₹15,469 cr | ₹4,062 cr | ₹3,369 cr | 26.3% | 21.8% | ₹14.00 | — | +47.8% |
| Q1 FY262025-06-30 | ₹13,786 cr | ₹3,372 cr | ₹2,279 cr | 24.5% | 16.5% | ₹9.50 | — | +6.0% |
| Q4 FY252025-03-31 | ₹12,816 cr | ₹2,761 cr | ₹2,150 cr | 21.5% | 16.8% | ₹9.00 | — | — |
| TTM (last 4 quarters) | ₹61,411 cr | ₹14,357 cr | ₹10,973 cr | 23.4% | 17.9% | ₹45.70 | — | — |
Consolidated figures as reported to the exchanges, shown in ₹ crore. OPM = operating profit margin. Updated automatically whenever a new quarter is filed.
Line-item results for the last six quarters as filed — sales, expenses, operating profit, interest, tax and profit after tax in ₹ crore.
| Particulars | Q2 FY272026-09-30 | Q1 FY272026-06-30 | Q4 FY262026-03-31 | Q3 FY262025-12-31 | Q1 FY262025-06-30 | Q4 FY252025-03-31 |
|---|---|---|---|---|---|---|
| Revenue / Sales | ₹16,199 cr | ₹15,184 cr | ₹14,560 cr | ₹15,469 cr | ₹13,786 cr | ₹12,816 cr |
| Total expenses | ₹12,288 cr | ₹11,627 cr | ₹11,808 cr | ₹11,407 cr | ₹10,414 cr | ₹10,055 cr |
| Gross profit | — | ₹12,220 cr | ₹11,759 cr | ₹12,524 cr | ₹10,971 cr | ₹10,178 cr |
| Operating profit (EBIT) | ₹3,986 cr | ₹3,557 cr | ₹2,752 cr | ₹4,062 cr | ₹3,372 cr | ₹2,761 cr |
| Operating margin | 24.6% | 23.4% | 18.9% | 26.3% | 24.5% | 21.5% |
| Interest cost | ₹74.67 cr | ₹99.67 cr | ₹85.89 cr | ₹78.36 cr | ₹74.8 cr | ₹49.14 cr |
| Profit before tax | ₹3,159 cr | ₹4,099 cr | ₹3,551 cr | ₹4,227 cr | ₹3,173 cr | ₹3,254 cr |
| Tax expense | ₹1,158 cr | ₹1,188 cr | ₹828 cr | ₹826 cr | ₹870 cr | ₹1,094 cr |
| Effective tax rate | 36.6% | 29.0% | 23.3% | 19.5% | 27.4% | 33.6% |
| Net profit (PAT) | ₹1,995 cr | ₹2,895 cr | ₹2,714 cr | ₹3,369 cr | ₹2,279 cr | ₹2,150 cr |
| Net profit margin | 12.3% | 19.1% | 18.6% | 21.8% | 16.5% | 16.8% |
| Basic EPS | ₹8.30 | ₹12.10 | ₹11.30 | ₹14.00 | ₹9.50 | ₹9.00 |
| Diluted EPS | — | ₹12.10 | ₹11.30 | ₹14.00 | ₹9.50 | ₹9.00 |
| Growth | Q2 FY27 | Q1 FY27 | Q4 FY26 | Q3 FY26 | Q1 FY26 | Q4 FY25 |
|---|---|---|---|---|---|---|
| Revenue YoY | — | +10.1% | +13.6% | — | — | — |
| Revenue QoQ | +6.7% | +4.3% | -5.9% | +12.2% | +7.6% | — |
| Operating profit YoY | — | +5.5% | -0.3% | — | — | — |
| Operating profit QoQ | +12.0% | +29.3% | -32.3% | +20.5% | +22.1% | — |
| Net profit YoY | — | +27.0% | +26.2% | — | — | — |
| Net profit QoQ | -31.1% | +6.7% | -19.4% | +47.8% | +6.0% | — |
| EPS YoY | — | +27.4% | +25.6% | — | — | — |
| EPS QoQ | -31.4% | +7.1% | -19.3% | +47.4% | +5.6% | — |
Full-year performance for SUN PHARMACEUTICAL IND L, useful for reading each quarter in context.
| Particulars | FY262026-03-31 | FY252025-03-31 | FY242024-03-31 | FY232023-03-31 |
|---|---|---|---|---|
| Revenue / Sales | ₹58,220 cr | ₹52,041 cr | ₹47,758 cr | ₹43,279 cr |
| Total expenses | ₹44,625 cr | ₹39,460 cr | ₹37,290 cr | ₹34,002 cr |
| Gross profit | ₹45,047 cr | ₹39,844 cr | ₹35,689 cr | ₹31,336 cr |
| Operating profit (EBIT) | ₹13,595 cr | ₹12,581 cr | ₹10,468 cr | ₹9,277 cr |
| Operating margin | 23.4% | 24.2% | 21.9% | 21.4% |
| Interest cost | ₹339 cr | ₹231 cr | ₹238 cr | ₹172 cr |
| Profit before tax | ₹15,119 cr | ₹13,752 cr | ₹11,088 cr | ₹9,408 cr |
| Tax expense | ₹3,554 cr | ₹2,772 cr | ₹1,439 cr | ₹848 cr |
| Effective tax rate | 23.5% | 20.2% | 13.0% | 9.0% |
| Net profit (PAT) | ₹11,479 cr | ₹10,929 cr | ₹9,576 cr | ₹8,474 cr |
| Net profit margin | 19.7% | 21.0% | 20.1% | 19.6% |
| Basic EPS | ₹47.80 | ₹45.60 | ₹39.90 | ₹35.30 |
| Diluted EPS | ₹47.80 | ₹45.60 | ₹39.90 | ₹35.30 |
Topline for Q2 FY27 came in at ₹16,199 cr, and ₹15,184 cr in the preceding Q1 FY27 quarter.
On a sequential basis revenue grew +6.7%. Sequential moves are the quickest read on demand momentum because they strip out the base effect of a year-old quarter, though seasonality can distort a single quarter.
Total expenses for the quarter were ₹12,288 cr, or 75.9% of revenue.
Net profit of ₹1,995 cr works out to a net margin of 12.3%.
Below the operating line, SUN PHARMACEUTICAL IND L reported profit before tax of ₹3,159 cr, a tax charge of ₹1,158 cr (effective rate 36.6%), interest cost of ₹74.67 cr. Reading these together with operating profit shows how much of the quarter's earnings were driven by the core business versus financing and tax movements.
Sequentially, net profit moved from ₹2,895 cr in Q1 FY27 to ₹1,995 cr in Q2 FY27, a change of -31.1%.
Across the trailing four quarters SUN PHARMACEUTICAL IND L has generated revenue of ₹61,411 cr and net profit of ₹10,973 cr, a trailing net margin of 17.9%. The trailing view smooths out one-off quarters and is the number most valuation multiples are built on.
On a full-year basis, FY26 revenue was ₹58,220 cr with net profit of ₹11,479 cr and EPS of ₹47.80, versus the prior year where revenue grew +11.9% and profit grew +5.0%.
For the coming quarters the numbers worth tracking on this page are revenue momentum, the operating margin trend, the interest burden and whether EPS keeps pace with profit growth. A single weak quarter matters less than the direction over three to four consecutive quarters.
No next results date is available in the board-meeting calendar. Statement figures update when Yahoo Finance makes them available; this is not an immediate exchange-filing feed.
Financial figures here are supplied through Yahoo Finance fundamentals and shown in ₹ crore, without adjustment. This is information and analysis, not investment advice.
| Board meeting date | Purpose | Details |
|---|---|---|
| 30 Oct 2026 | Financial Results | Board Meeting Intimation for consideration and approval the Unaudited Financial Results for the quarter and half year ended 30 September 2026 |
In Q2 FY27 (quarter ended 30 Sept 2026), SUN PHARMACEUTICAL IND L reported revenue of ₹16,199 cr and net profit of ₹1,995 cr. EPS stood at ₹8.30.
SUN PHARMACEUTICAL IND L posted a net profit margin of 12.3% and an operating margin of 24.6% in Q2 FY27. On a trailing twelve-month basis, revenue is ₹61,411 cr and net profit ₹10,973 cr.
SUN PHARMACEUTICAL IND L net profit changed -31.1% quarter on quarter, from ₹2,895 cr in Q1 FY27 to ₹1,995 cr in Q2 FY27.
SUN PHARMACEUTICAL IND L has not yet intimated its next results date to the exchange. This page updates automatically from the exchange board-meeting calendar.
Our latest SUNPHARMA results coverage — "Sun Pharmaceutical Industries Limited Q2 FY27 Results: Net Profit ₹1,995 cr" — breaks down revenue, profit, margins and management commentary.
For FY26, SUN PHARMACEUTICAL IND L reported full-year revenue of ₹58,220 cr and net profit of ₹11,479 cr, with EPS of ₹47.80.
SUNPHARMA has held 1 recent board meetings for financial results, the last on 30 Oct 2026.
Results dates: NSE board-meeting calendar. Financial figures: Yahoo Finance fundamentals, not a direct exchange filing feed. Last successful data fetch 31 Oct 2026. Figures can be delayed; results change only when the provider publishes them. For information only, not investment advice.
